Biosimilars Clinical Pharmacology Drug Development FDA Approval 
Agency IQ
SEPTEMBER 29, 2023
The proposed rule will identify certain bulk drug substances that FDA has considered and is proposing to place on the 503A Bulks List and certain bulk drug substances that FDA has considered and is proposing not to include on the 503A Bulks List.
Agency IQ
OCTOBER 27, 2023
The proposed rule will identify certain bulk drug substances that FDA has considered and is proposing to place on the 503A Bulks List and certain bulk drug substances that FDA has considered and is proposing not to include on the 503A Bulks List.
Agency IQ
DECEMBER 1, 2023
The proposed rule will identify certain bulk drug substances that FDA has considered and is proposing to place on the 503A Bulks List and certain bulk drug substances that FDA has considered and is proposing not to include on the 503A Bulks List.
Expert insights. Personalized for you.
40 
Let's personalize your content